Rockwell Medical, Inc. (RMTI): Price and Financial Metrics
GET POWR RATINGS... FREE!
RMTI POWR Grades
- RMTI scores best on the Value dimension, with a Value rank ahead of 68.44% of US stocks.
- RMTI's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
- RMTI's current lowest rank is in the Quality metric (where it is better than 8.88% of US stocks).
RMTI Stock Summary
- Rockwell Medical Inc's market capitalization of $85,483,031 is ahead of merely 13.08% of US-listed equities.
- Rockwell Medical Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 79.26% of US listed stocks.
- Rockwell Medical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -39.49%, greater than the shareholder yield of only 6.4% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Rockwell Medical Inc, a group of peers worth examining would be VERB, CPHI, AIH, CYD, and NAKD.
- RMTI's SEC filings can be seen here. And to visit Rockwell Medical Inc's official web site, go to www.rockwellmed.com.
RMTI Price Target
For more insight on analysts targets of RMTI, see our RMTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.25 | Average Broker Recommendation | 1.5 (Moderate Buy) |
RMTI Stock Price Chart Interactive Chart >
RMTI Price/Volume Stats
| Current price | $0.99 | 52-week high | $2.12 |
| Prev. close | $0.93 | 52-week low | $0.83 |
| Day low | $0.92 | Volume | 3,005,200 |
| Day high | $1.06 | Avg. volume | 1,790,960 |
| 50-day MA | $0.95 | Dividend yield | N/A |
| 200-day MA | $1.13 | Market Cap | 92.67M |
Rockwell Medical, Inc. (RMTI) Company Bio
Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. The company was founded in 1995 and is based in Wixom, Michigan.
Latest RMTI News From Around the Web
Below are the latest news stories about Rockwell Medical Inc that investors may wish to consider to help them evaluate RMTI as an investment opportunity.
Rockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive License Agreement for the Rights to Commercialize Triferic® in Turkey- With approximately 65,000 patients receiving hemodialysis annually, Turkey represents a significant and expanding market opportunity -WIXOM, Mich. and ANKARA, Turkey, June 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, and Drogsan Pharmaceuticals, a leading pharmaceutical company in Turkey with an established pre |
When Will Rockwell Medical, Inc. (NASDAQ:RMTI) Become Profitable?Rockwell Medical, Inc. ( NASDAQ:RMTI ) is possibly approaching a major achievement in its business, so we would like to... |
Rockwell Medical, Inc. to Present at the 2021 LD Micro Invitational XIWIXOM, Mich., June 03, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team will be presenting at the 2021 LD Micro Invitational XI on June 10th at 2:30pm EDT. The conference will be held in a virtual format. A live webcast of the event will be available from the |
Rockwell Medical's (RMTI) CEO Russell Ellison on Q1 2021 Results - Earnings Call TranscriptRockwell Medical, Inc. (RMTI) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Claudia Styslinger – Investor Relations Russell Ellison – President and Chief Executive Officer Russell Skibsted – Executive Vice President, Chief Financial Officer and Chief Business Officer Marc Hoffman – Chief Medical Officer Conference... |
Rockwell Medical, Inc. to Report First Quarter 2021 Financial and Operating Results on May 17, 2021WIXOM, Mich., May 03, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, May 17, 2021, at 4:30 p.m. ET to discuss its financial results for the three months ended March 31, 2021, and recent operational highlights. To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 7870946. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archiv... |
RMTI Price Returns
| 1-mo | 9.89% |
| 3-mo | -26.12% |
| 6-mo | -12.39% |
| 1-year | -50.50% |
| 3-year | -81.36% |
| 5-year | -88.50% |
| YTD | -1.98% |
| 2020 | -58.61% |
| 2019 | 7.96% |
| 2018 | -61.17% |
| 2017 | -11.15% |
| 2016 | -36.04% |
Continue Researching RMTI
Want to do more research on Rockwell Medical Inc's stock and its price? Try the links below:Rockwell Medical Inc (RMTI) Stock Price | Nasdaq
Rockwell Medical Inc (RMTI) Stock Quote, History and News - Yahoo Finance
Rockwell Medical Inc (RMTI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...